Association of Vascular Endothelial Growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) with Radiotherapy Response in High-Grade Sarcomas
Abstract
Background: Sarcoma is a rare malignant aggressive tumor originating from mesenchymal elements. High-grade sarcoma has a poor prognosis. The mortality rate of high-grade sarcomas is 50–75%. Radiotherapy is needed in high-grade sarcoma. Radioresistance in the high-grade sarcoma is still common. Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) are molecular markers that play a role in radioresistance. This study aimed to analyze the association of VEGF and mTOR with radiotherapy response in high-grade sarcoma.
Method: This study was an analytic observational study with a cross-sectional design. The minimum samples based on Lameshow’s formula included 40 selected paraffin-embedded tissue blocks from biopsy high-grade sarcoma, consisting of 20 samples of radioresistance and 20 samples of radiosensitive. Immunohistochemistry staining for VEGF and mTOR were performed on all samples. Statistical analysis used the Chi-Square test. The significance of the data was obtained when p-value <0.05.
Result: High immunoexpression of VEGF (OR = 17, p < 0.05) and mTOR in high-grade sarcoma showed a significant association with radiotherapy response (OR = 16, p < 0.05). The stepwise logistic regression analysis revealed that both VEGF and mTOR immunoexpression influenced radiotherapy response simultaneously.
Conclusion: In this study, which used a minimum sample, it can be concluded that the higher VEGF and mTOR immunoexpression showed the higher radioresistance in high-grade sarcoma.
Keywords
DOI: 10.33371/ijoc.v16i2.868
Article Metrics
Abstract View: 173, 
PDF Download: 122
References
Schaefer IM, Cote GM, Hornick JL. Contemporary
Sarcoma Diagnosis, Genetics, and Genomics. J Clin
Oncol. 2018 Jan 10;36(2):101–110.
Tobias J, Hochhauser D. Cancer and its Management.
th Ed. West Sussex: John Wiley & Sons, Ltd; 2015.
Götzl R, Sterzinger S, Semrau S, et al. Patient’s
quality of life after surgery and radiotherapy for
extremity soft tissue sarcoma - a retrospective
single-centerstudyovertenyears. Health Qual Life
Outcomes. 2019;170.
Wortman JR, Tirumani SH, Jagannathan JP, et al.
Radiation Theraphy for Soft Tissue Sarcoma:a Primer
for Radiologist. Radio Graphics. 2016;36(2):554–72.
Spencer RM, Junior SA, Ferreira FO, et al. Neoadjuvant Hypofractionated Radiotherapy and
Chemotherapy in High-Grade Extremity Soft Tissue
Sarcomas: Phase 2 Clinical Trial Protocol. JMIR Res
Protoc. 2017 May 25;6(5):e97.
Ward WG, Corey RM. The Burden of Musculoskeletal
Disease in The United States: Mortality and Survival
Rates [Internet]. The United States: BMUS; 2015
[Cited 2019 Dec 2]. Available from: https://www.
boneandjointburden.org/2014-report/viiiab24/
mortality-and-survival-rates.
Loureiro da Silva AJ, Carvalho C, Jacobetty M, et
al. Neoadjuvant Trabectedin plus Radiotherapy in High-Grade Sarcoma of the Leg: A Case Report. Case Rep Oncol. 2018 Jul 18;11(2):499-504.
Nurhidayat AA, Usman HA, Hernowo BS. The role
of cyclin D1 and vascular endothelial growth factor (VEGF) in radiotherapy response of undifferentiated
nasopharyngeal carcinoma. Jambi Medical Journal.
;50(4):105–14.
Wibisono F, Suryanti S, Hernowo BS. Correlation of
VEGF Expression and Microvesel Density with
Cervical Adenocarcinoma Radiotherapy Resp Jambi Medical Journal. 2014;2(2):167–77.
Kim M-K, Kim TJ, Sung CO, Choi CH. High expression
of mTOR is associated with radiation resistancein cervical cancer. J Gynecol Oncol. 2010;21(3):181-5.
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf
W. Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy forTreatment. Plos One. 2013;17;8(6).
Kurnia I, Fajriansyah, Siregar B, et al. Ekspresi mTOR
dan BAX pada Sel Kanker Servik yang diobati dengan
Radioterapi. National Seminar on Health and Environmental Safety IX; 2014 Juni 19. Jakarta.
PTKMR-BATAN, Universitas Indonesia, KEMENKES-RI,
Universitas Pakuan; 2014
Sastroasmoro S, Ismail S. Dasar-dasar Metodologi
Penelitian Klinis. Edisi 5. Jakarta: Sagung Seto. 2014
Geoffrey M, DeMatteo D, Festinger D. Essentials of
Research Design and Methodology. New Jer: John
Wiley & Son; 2005.
Dahlan MS. Besar sampel dan cara pengambilan
sampel dalam penelitian kedokteran dan kesehatan.
nd ed. Jakarta: Salemba Medika; 2013
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization Classification of
Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC; 2013.
Armanza F, Andrijono A, Sutrisna B. Serum Level
of Vascular Endothelial Growth Factor (VEGF) can
be used to Assess Response of Radiation Therapy
in Cervical Cancer. Indonesian Journal of Obstetric
and Gynecology. 2014;2(1):40–5.
Wanigasooriya K, Tyler R, Barros-Silva JD, Sinha Y,
Ismail T, Beggs AD. Radiosensitising Cancer Using
Phosphatidylinositol-3-Kinase (PI3K), Protein Kinase
B (AKT) or Mammalian Target of Rapamycin (mTOR)
Inhibitors. Cancers (Basel). 2020 May 18;12(5):1278.
Setyawan A, Djakaria HM. Literature review. Basic
Effects of Radiation on Tissue. Radioterapi & Onkologi Indonesia. 2014;5(1):25–33.
Giuliano S, Pagès G. Mechanisms of resistance to
anti-angiogenesis therapies. Biochimie. 2013 Jun;95(6):1110–9.
Simon, Yoon MC, Sunghyun S. HIFs and VEGF in
Sarcoma Progression, Metastasis and Radiation
Response. Grantome. 2020. https://grantome.com/ grant/NIH/R01-CA158301-05
Yoon C, Lee HJ, Park DJ, et al. Hypoxia-Activated
Chemotherapeutic TH-302 Enhances The Effects of
VEGF-A Inhibition and Radiation on Sarcomas. British
Journal of Cancer. 2015;113(1).
Bzowska M, Mezyk-Kopec R, Prochnicki T, et al.
A n t i b o d y - b a s e d a n t i a n g i o g e n i c a n d
antilymphangiogenic therapies to prevent tumor
growth and progression. Acta Biochimica Polonica.
;60(3).
Tirumani SH, Fairchild A, Krajewski KM, et al. AntiVEGF molecular targeted therapies in common solid
malignancies: comprehensive update for radiologists.
Radiographics. 2015 Mar-Apr;35(2):455–74.
Maud V, Annelies D, Xavier S, et al. Advances in Cancer: Anti-Angiogenic Therapy Combined with Chemoradiotherapy for Patients with Localized Advanced Rectal Cancer. Research & Treatment.
Chédeville AL, Madureira PA. The Role of Hypoxia
in Glioblastoma Radiotherapy Resistance. Cancers
(Basel). 2021 Feb 1;13(3).
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License...
Email this article 
